BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?
about
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.Lupus nephritis: lessons from murine modelsMyeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice.Innate pathways to B-cell activation and tolerance.Chronic alloantibody mediated rejection.BAFF: a local and systemic target in autoimmune diseases.Emerging biotherapies for Sjögren's syndrome.Anticytokine therapy in systemic lupus erythematosus.Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity.BAFF inhibition: a new class of drugs for the treatment of autoimmunity.An update on belimumab for the treatment of lupus.BAFF and selection of autoreactive B cellsBelimumab: targeted therapy for lupus.Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.IL-2, IL-4, IFN-γ or TNF-α enhances BAFF-stimulated cell viability and survival by activating Erk1/2 and S6K1 pathways in neoplastic B-lymphoid cells.What do we know about the role of regulatory B cells (Breg) during the course of infection of two major parasitic diseases, malaria and leishmaniasis?Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice.B cells twist and shout.Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus.Delayed onset of autoreactive antibody production and M2-skewed macrophages contribute to improved survival of TACI deficient MRL-Fas/Lpr mouse.
P2860
Q33803763-BAD2B1A0-34FC-4937-AF24-FB5AA928335CQ33998360-CB4B698C-7705-4608-80C1-4C51B18B37ABQ34044394-424A580E-D8D8-4FE8-B546-82A32706C5D5Q36172913-6DE8717A-F59A-42C4-9C80-32CD791AB752Q37058050-711B2D00-2820-4695-B4F0-4E150CB04B16Q37593590-2C1349A6-DBD2-41E7-9514-7C080D843E16Q37729176-C4120466-A590-486E-82DF-6131CE844FC4Q37800306-FC251040-BDA6-42BF-9A20-0F92A31EE5A9Q37813704-91317AFC-B2EE-49BC-935F-7D239CE7752BQ37844764-FAFBFEF9-46F6-4699-A134-8EA46C3E4204Q37850690-2F6FA62F-BEA4-40A6-9F33-E31B3459D06CQ37900758-50D5F42F-D5CE-4BE9-8301-0411DDFC9DF6Q38084687-EF7A71A5-1E18-4A90-939A-F9A7A216277AQ38903921-936441C8-FF67-4C79-818E-C952F734CBAEQ39729327-8BD6D0A4-81E5-4914-AAF8-D69D9954EDA5Q40273988-3547BAAA-EBD8-40D9-89ED-F48A57E1568EQ40789497-28A4E63B-DF6C-489B-9D58-5E298F3C233DQ42566796-23BA4FF3-CD7C-4B96-A671-AFF2F276D779Q42706248-93131B45-F6AD-4DB7-8D2D-C83E99B8C6E1Q47547374-3C648532-8139-49B8-B8CC-7532F3779C76Q47550170-ECDD7622-C6D0-452D-B4D7-F59DB05C58E6
P2860
BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?
@en
BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?
@nl
type
label
BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?
@en
BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?
@nl
prefLabel
BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?
@en
BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?
@nl
P1476
BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?
@en
P2093
Meera Ramanujam
P304
P356
10.1111/J.1600-065X.2008.00625.X
P577
2008-06-01T00:00:00Z